Ann Cunningham's most recent trade in VistaGen Therapeutics Inc was a trade of 14,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Sept. 6, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics Inc | Ann M. Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Ann Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Ann Cunningham | Director, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Ann Cunningham | Director, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2021 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) |